Transforming Prostate Cancer Care: Aquilant Partners with Biobot Surgical to Launch the Mona Lisa Robotic Platform in the UK

Aquilant, part of Healthcare 21 UK, is delighted to announce a new partnership with Biobot Surgical to bring the innovative Mona Lisa Robotic Platform for transperineal prostate biopsy to healthcare providers and patients across the UK.

This exclusive partnership marks a significant milestone in our ongoing commitment to advancing clinical practice and improving patient outcomes. The Mona Lisa Robotic Platform is a state-of-the-art system that enhances the accuracy, safety, and efficiency of prostate biopsies. Its advanced robotic guidance and precision targeting empower clinicians to deliver better results while reducing the risks associated with traditional biopsy methods.

Graeme Dickson, Urology National Sales Manager at Healthcare 21, commented:
“We are delighted to partner with Biobot Surgical to bring the Mona Lisa Robotic Platform to healthcare providers and patients in the UK. This partnership underscores our commitment to delivering cutting-edge technologies that transform patient care and support clinicians with the very best tools available.”

Steve Matthews, UK Sales Director at Healthcare 21, added:
“At Healthcare 21, we are committed to responding quickly to the needs of the UK healthcare market. With the NHS aiming to reduce elective waiting times by 2029, new technologies such as robotics will be essential. They not only increase efficiency but also improve outcomes, speed up recovery, and shorten hospital stays. I am thrilled about this partnership and the benefits it will bring to clinicians and patients.”

Giansante Alessandrini, Commercial Director at Biobot Surgical EMEA, also commented:
“We are excited to collaborate with Healthcare 21, whose expertise and reach in the UK healthcare sector will be instrumental in making Mona Lisa accessible to more clinicians and patients. Together, we aim to set a new standard in prostate cancer diagnostics and care.”

The minimally invasive approach of the Mona Lisa system reduces infection risk and supports the growing demand for safer, more effective prostate cancer care. As the exclusive UK distributor, Healthcare 21 will provide comprehensive support, training, and service to healthcare institutions nationwide.